Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques.

Yuko Shirakawa, Takashi Yoshiura, Akio Hiwatashi, Koji Yamashita, Hironori Kamano, Yoshiyuki Shioyama, Kouichiro Abe, Toshiyuki Amano, Akira Nakamizo, Koji Yoshimoto, Hiroyuki Honda, Rina Torisu, Satoshi Suzuki, Hiroshi Honda

Research output: Contribution to journalArticle

Abstract

Concurrent temozolomide (TMZ) and radiotherapy became the new standard of care for patients diagnosed with glioblastoma multiforme (GBM). Recently, there has been an increasing awareness of progressive and enhancing lesions on MR images immediately after treatment. These lesions may be a treatment effect, so-called pseudoprogression. We experienced one case pathologically and clinically diagnosed as pseudoprogression. The lesion showed a high apparent diffusion coefficient on diffusion-weighted imaging, low blood volume on perfusion imaging, and low uptake of 18F-fluorodeoxyglucose on positron emission tomography. The lesion was pathologically diagnosed as pseudoprogression after additional surgical resection.

Original languageEnglish
Pages (from-to)257-264
Number of pages8
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume101
Issue number12
Publication statusPublished - Dec 1 2010

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques.'. Together they form a unique fingerprint.

  • Cite this